123 related articles for article (PubMed ID: 11270929)
1. Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".
Potenza MN; McDougle CJ
J Clin Psychopharmacol; 2001 Apr; 21(2):246-7. PubMed ID: 11270929
[No Abstract] [Full Text] [Related]
2. Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".
Demb HB; Roychoudhury K
J Clin Psychopharmacol; 2000 Oct; 20(5):580-1. PubMed ID: 11001245
[No Abstract] [Full Text] [Related]
3. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
Potenza MN; Holmes JP; Kanes SJ; McDougle CJ
J Clin Psychopharmacol; 1999 Feb; 19(1):37-44. PubMed ID: 9934941
[TBL] [Abstract][Full Text] [Related]
4. Open-label study of olanzapine in children with pervasive developmental disorder.
Kemner C; Willemsen-Swinkels SH; de Jonge M; Tuynman-Qua H; van Engeland H
J Clin Psychopharmacol; 2002 Oct; 22(5):455-60. PubMed ID: 12352267
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
Malone RP; Cater J; Sheikh RM; Choudhury MS; Delaney MA
J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):887-94. PubMed ID: 11501687
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine in PDD.
Horrigan JP; Barnhill LJ; Courvoisie HE
J Am Acad Child Adolesc Psychiatry; 1997 Sep; 36(9):1166-7. PubMed ID: 9291716
[No Abstract] [Full Text] [Related]
7. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
Hollander E; Wasserman S; Swanson EN; Chaplin W; Schapiro ML; Zagursky K; Novotny S
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):541-8. PubMed ID: 17069543
[TBL] [Abstract][Full Text] [Related]
8. Use of atypical neuroleptics in child and adolescent psychiatry.
Toren P; Laor N; Weizman A
J Clin Psychiatry; 1998 Dec; 59(12):644-56. PubMed ID: 9921698
[TBL] [Abstract][Full Text] [Related]
9. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Frazier JA; Biederman J; Tohen M; Feldman PD; Jacobs TG; Toma V; Rater MA; Tarazi RA; Kim GS; Garfield SB; Sohma M; Gonzalez-Heydrich J; Risser RC; Nowlin ZM
J Child Adolesc Psychopharmacol; 2001; 11(3):239-50. PubMed ID: 11642474
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine treatment for patients with schizophrenia and cocaine abuse.
Tsuang J; Marder SR; Han A; Hsieh W
J Clin Psychiatry; 2002 Dec; 63(12):1180 -1. PubMed ID: 12530415
[No Abstract] [Full Text] [Related]
11. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
12. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
13. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
[TBL] [Abstract][Full Text] [Related]
14. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.
Lane HY; Guo SC; Hwang TJ; Chen YS; Cheng JJ; Lee YC; Hong CJ; Hwu HG; Chang WH
J Clin Psychopharmacol; 2002 Oct; 22(5):530-2. PubMed ID: 12352282
[No Abstract] [Full Text] [Related]
15. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.
Stavrakaki C; Antochi R; Emery PC
J Psychiatry Neurosci; 2004 Jan; 29(1):57-60. PubMed ID: 14719051
[TBL] [Abstract][Full Text] [Related]
16. Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified.
Tateno M; Teshirogi H; Kamasaki H; Saito T
Psychiatry Clin Neurosci; 2008 Dec; 62(6):752. PubMed ID: 19068020
[No Abstract] [Full Text] [Related]
17. Weight gain and antipsychotic medications.
Aquila R; Emanuel M
J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
[No Abstract] [Full Text] [Related]
18. Hyperglycemia from olanzapine treatment in adolescents.
Bloch Y; Vardi O; Mendlovic S; Levkovitz Y; Gothelf D; Ratzoni G
J Child Adolesc Psychopharmacol; 2003; 13(1):97-102. PubMed ID: 12804130
[TBL] [Abstract][Full Text] [Related]
19. A prospective, open-label trial of olanzapine in adolescents with schizophrenia.
Findling RL; McNamara NK; Youngstrom EA; Branicky LA; Demeter CA; Schulz SC
J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):170-5. PubMed ID: 12544176
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
McDougle CJ; Stigler KA; Erickson CA; Posey DJ
J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
